Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders for Aprea Therapeutics, Inc., held on June 16, 2026. The company is incorporated in Delaware and its common stock trades on the NASDAQ under the symbol APRE. The filing details the voting outcomes for six proposals submitted to shareholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Of the 12,382,776 shares entitled to vote, 8,268,451 shares (approximately 66.8%) were represented, constituting a quorum. The material outcomes were:
- Director Elections: Stockholders elected Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D., as Class I directors. Bernd R. Seizinger received the highest number of withheld votes (386,956) compared to the other nominees.
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation authorizing the Board to effect a reverse stock split at a ratio between 1-for-3 and 1-for-8. The Board retains sole discretion to determine the exact ratio and timing.
- Accounting Firm: Ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for fiscal year 2026.
- Executive Compensation: Approved the compensation of named executive officers (Say-on-Pay) and voted for an annual (1-year) frequency for future advisory votes on compensation.
- Adjournment: Approved the ability to adjourn the meeting to solicit additional proxies if necessary for Proposal 3 (which passed).
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, guidance, or specific risks beyond the standard disclosure that the reverse stock split ratio and timing are at the Board's discretion. The approval of the reverse stock split suggests the company is taking measures to potentially improve stock liquidity or meet listing requirements, though the filing does not explicitly state the rationale.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once announced by the Board, as the filing only authorized a range (1-for-3 to 1-for-8).
- Review the definitive proxy statement (Schedule 14A filed April 30, 2026) for detailed biographies of the newly elected directors and the full rationale for the reverse stock split.
- Monitor future filings for the actual implementation of the reverse stock split and any impact on share count and price.
- Note the significant number of broker non-votes (2,386,385) on director elections and executive compensation, indicating shares held in street name where brokers lacked discretionary voting power.